When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [16] [17] It was developed by Regeneron Pharmaceuticals. It is an inhibitor of vascular endothelial growth factor (VEGF).

3. Ranibizumab - Wikipedia

   en.wikipedia.org/wiki/Ranibizumab

   Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

4. Anti-VEGF - Wikipedia

   en.wikipedia.org/wiki/Anti-VEGF

   By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...

5. Regeneron's Eylea: The Anatomy Of A Blockbuster Drug - AOL

   www.aol.com/2014/03/04/regenerons-eylea-the...

   For premium support please call: 800-290-4726 more ways to reach us

6. Competitor? No. Worrisome? Yes. - AOL

   www.aol.com/2012/06/13/competitor-no-worrisome-yes

   Regeneron Pharmaceuticals (NAS: REGN) traded down more than 12% today after privately held Ophthotech released data on its macular degeneration drug. Funny thing is, Ophthotech's drug, Fovista ...

7. US FDA approves two biosimilars for blockbuster eye drug Eylea

   www.aol.com/news/us-fda-approves-two-biosimilars...

   The agency approved Biocon Biologics' Yesafili as well as Samsung Bioepis and Biogen's Opuviz, while also allowing interchangeability, or the drug's substitution with biosimilars without the need ...

8. Intravitreal injection - Wikipedia

   en.wikipedia.org/wiki/Intravitreal_injection

   Intravitreal injection has then become more common and a surge in the number of injections performed could be seen. [10] Six extra medications, namely triamcinolone acetonide, ranibizumab (Lucentis), aflibercept (Eylea/Zaltrap), dexamethasone, ocriplasmin and fluocinolone acetonide were approved for this injection by the end of 2014. [2]

9. List of largest selling pharmaceutical products - Wikipedia

   en.wikipedia.org/wiki/List_of_largest_selling...

   Eylea 6551 5830 13 infliximab: Remicade 5908 ... ∆ vs 2014 1 Adalimumab: Humira Biologic ... Lucentis: Ranibizumab: 460,621